Fig. 1From: Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancerClaudin (CLDN) 3. Positive expression in BRCA1 breast cancer (BC) (a) and negative control (isotypic antibody) (b). Positive CLDN4 expression in BRCA1-mutated BC (c), negative control of CLDN4 (isotypic antibody) (d). Positive CLDN7 in BRCA2 BC (e), negative CLDN7 in BRCA1-related tumor (f), and negative control of CLDN7 (isotypic antibody) (g). Positive CK5 staining in BRCA1 BC (h)Back to article page